The subject of this publication is the conclusion of contracts in accordance with Section 130a, Paragraph 8 of Book V of the Social Code (SGB V) on the following active substances as part of a so-called open house procedure:

Natalizumab, only in the dosage form IFK (L04AA23)

Under standard standard contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the said active substance.

The earliest contract start date is 01.01.2022. On this basis, the contract period is a maximum of 24 months.

Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the named active ingredient.

The earliest contract start date is 01.01.2022. On this basis, the contract period is a maximum of 24 months.